98%
921
2 minutes
20
Testicular orphan nuclear receptor 4 (TR4) is an orphan member of the nuclear receptor superfamily with diverse physiological functions. Using TR4 knockout (TR4(-/-)) mice to study its function in cardiovascular diseases, we found reduced cluster of differentiation (CD)36 expression with reduced foam cell formation in TR4(-/-) mice. Mechanistic dissection suggests that TR4 induces CD36 protein and mRNA expression via a transcriptional regulation. Interestingly, we found this TR4-mediated CD36 transactivation can be further enhanced by polyunsaturated fatty acids (PUFAs), such as omega-3 and -6 fatty acids, and their metabolites such as 15-hydroxyeico-satetraonic acid (15-HETE) and 13-hydroxy octa-deca dieonic acid (13-HODE) and thiazolidinedione (TZD)-rosiglitazone. Both electrophoretic mobility shift assays (EMSA) and chromatin immunoprecipitation (ChIP) assays demonstrate that TR4 binds to the TR4 response element located on the CD36 5'-promoter region for the induction of CD36 expression. Stably transfected TR4-siRNA or functional TR4 cDNA in the RAW264.7 macrophage cells resulted in either decreased or increased CD36 expression with decreased or increased foam cell formation. Restoring functional CD36 cDNA in the TR4 knockdown macrophage cells reversed the decreased foam cell formation. Together, these results reveal an important signaling pathway controlling CD36-mediated foam cell formation/cardiovascular diseases, and findings that TR4 transactivation can be activated via its ligands/activators, such as PUFA metabolites and TZD, may provide a platform to screen new drug(s) to battle the metabolism syndrome, diabetes, and cardiovascular diseases.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726407 | PMC |
http://dx.doi.org/10.1073/pnas.0905724106 | DOI Listing |
ACS Appl Mater Interfaces
September 2025
Department of Mechanical & Industrial Engineering, Louisiana State University, Baton Rouge, Louisiana 70803, United States.
With the rapid advancement in autonomous vehicles, 5G and future 6G communications, medical imaging, spacecraft, and stealth fighter jets, the frequency range of electromagnetic waves continues to expand, making electromagnetic interference (EMI) shielding a critical challenge for ensuring the safe operation of equipment. Although some existing EMI shielding materials offer lightweight construction, high strength, and effective shielding, they struggle to efficiently absorb broadband electromagnetic waves and mitigate dimensional instability and thermal stress caused by temperature fluctuations. These limitations significantly reduce their service life and restrict their practical applications.
View Article and Find Full Text PDFACS Appl Mater Interfaces
September 2025
Department of Chemical Engineering, Faculty of Engineering, Chulalongkorn University, Bangkok 10330, Thailand.
The accumulation of nitrate (NO) from agricultural runoff poses a growing threat to ecosystems and public health. Converting nitrate into ammonia (NH) through the electrochemical nitrate reduction reaction (NORR) offers a promising strategy to mitigate environmental contamination while creating a sustainable circular route to fertilizer production. However, achieving high NH production and energy efficiency remains challenging.
View Article and Find Full Text PDFFront Bioeng Biotechnol
August 2025
Solventum, St. Paul, MN, United States.
Introduction: Not all wound patients are candidates for surgical debridement. A felted, reticulated open cell foam with an array of 10 mm holes (VFCC) for use with instillation therapy has been used to eliminate non-viable tissue from patient wound beds. The mechanisms for this have not been fully elucidated.
View Article and Find Full Text PDFMater Today Bio
October 2025
School of Public Health, Key Laboratory of Emergency and Trauma of Ministry of Education, Hainan Medical University, Haikou, 571199, China.
The development of controllable nanoplatforms with disease-specific responsiveness and programmable therapeutic functions is vital for treating complex cardiovascular diseases such as atherosclerosis. Herein, we present an intelligent, next-generation nanoplatform (HALA@AgS) that integrates enzyme-responsive dual-drug delivery with NIR-II imaging-guided photothermal therapy (PTT), enabling triple-stimuli synergy of enzyme, light, and multi-drug co-activation. This modular design enables stable nanoassemblies with high drug-loading capacity and selective disassembly in enzyme-rich plaque microenvironments, achieving controlled dual-drug release exceeding 80 % within 72 h.
View Article and Find Full Text PDFAtherosclerosis (AS) is a significant contributor to cardiovascular events. Recent studies have demonstrated that ferroptosis of foam cells is a significant driver of AS. Nevertheless, insights into the precise antiferroptosis therapies remain limited.
View Article and Find Full Text PDF